Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN

Emerging Risk Factors, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063 Kamstrup, 2009, GEnetically elevated lipoprotein(a) and increased risk of myocardial infarction, JAMA, 301, 2331, 10.1001/jama.2009.801 Kamstrup, 2013, Extreme lipoprotein(a) levels and improved cardiovascular risk prediction, J. Am. Coll. Cardiol., 61, 1146, 10.1016/j.jacc.2012.12.023 Clarke, 2009, Genetic variants associated with Lp(a) lipoprotein level and coronary disease, N. Engl. J. Med., 361, 2518, 10.1056/NEJMoa0902604 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Cholesterol Treatment Trialists, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5 Hopkins, 1998, Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI family heart study, Atherosclerosis, 141, 333, 10.1016/S0021-9150(98)00174-9 Kronenberg, 1999, Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study, Circulation, 100, 1154, 10.1161/01.CIR.100.11.1154 von Eckardstein, 2001, Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk, J. Am. Coll. Cardiol., 37, 434, 10.1016/S0735-1097(00)01126-8 Luc, 2002, Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study, Atherosclerosis, 163, 377, 10.1016/S0021-9150(02)00026-6 Suk Danik, 2006, Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women, JAMA, 296, 1363, 10.1001/jama.296.11.1363 O'Donoghue, 2014, Lipoprotein(a) for risk assessment in patients with established coronary artery disease, J. Am. Coll. Cardiol., 63, 520, 10.1016/j.jacc.2013.09.042 Afshar, 2016, Lipoprotein(a) interactions with low-density lipoprotein cholesterol and other cardiovascular risk factors in premature acute coronary syndrome (ACS), J. Am. Heart Assoc., 5 Nicholls, 2011, Impact of statins on progression of atherosclerosis: rationale and design of SATURN (study of coronary atheroma by InTravascular ultrasound: effect of rosuvastatin versus AtorvastatiN), Curr. Med. Res. Opin., 27, 1119, 10.1185/03007995.2011.570746 Nicholls, 2011, Effect of two intensive statin regimens on progression of coronary disease, N. Engl. J. Med., 365, 2078, 10.1056/NEJMoa1110874 Nicholls, 2010, Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome, J. Am. Coll. Cardiol., 55, 2399, 10.1016/j.jacc.2010.02.026 Marcovina, 2000, Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a), Clin. Chem., 46, 1956, 10.1093/clinchem/46.12.1956 Nordestgaard, 2010, Lipoprotein(a) as a cardiovascular risk factor: current status, Eur. Heart J., 31, 2844, 10.1093/eurheartj/ehq386 Libby, 2005, The forgotten majority: unfinished business in cardiovascular risk reduction, J. Am. Coll. Cardiol., 46, 1225, 10.1016/j.jacc.2005.07.006 Khera, 2014, Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin), Circulation, 129, 635, 10.1161/CIRCULATIONAHA.113.004406 Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N. Engl. J. Med., 359, 2195, 10.1056/NEJMoa0807646 Baldassarre, 1996, Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients, Stroke, 27, 1044, 10.1161/01.STR.27.6.1044 Nicholls, 2010, Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy, J. Lipid Res., 51, 3055, 10.1194/jlr.M008961 Maher, 1995, Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a), JAMA, 274, 1771, 10.1001/jama.1995.03530220037029 Gaw, 2000, Is lipoprotein(a)-cholesterol a better predictor of vascular disease events than total lipoprotein(a) mass? A nested case control study from the West of Scotland Coronary Prevention Study, Atherosclerosis, 148, 95, 10.1016/S0021-9150(99)00259-2 Schreiner, 1993, Lipoprotein[a] as a risk factor for preclinical atherosclerosis, Arterioscler. Thromb., 13, 826, 10.1161/01.ATV.13.6.826 Hartmann, 2006, Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries, J. Am. Coll. Cardiol., 48, 446, 10.1016/j.jacc.2006.03.047 Hikita, 2013, Lipoprotein(a) is an important factor to determine coronary artery plaque morphology in patients with acute myocardial infarction, Coron. Artery Dis., 24, 381, 10.1097/MCA.0b013e3283622329 Niccoli, 2016, Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease, Atherosclerosis, 246, 214, 10.1016/j.atherosclerosis.2016.01.020 Bos, 2015, Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia, Atherosclerosis, 242, 226, 10.1016/j.atherosclerosis.2015.07.024 Hervio, 1993, Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?, Blood, 82, 392, 10.1182/blood.V82.2.392.392 Feric, 2008, Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation, J. Thromb. Haemostasis, 6, 2113, 10.1111/j.1538-7836.2008.03183.x Puri, 2014, Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN, Eur. eart J. Cardiovasc. Imaging, 15, 380, 10.1093/ehjci/jet251 Puri, 2015, Impact of statins on serial coronary calcification during atheroma progression and regression, J. Am. Coll. Cardiol., 65, 1273, 10.1016/j.jacc.2015.01.036 Tsimikas, 2016, The re-emergence of lipoprotein(a) in a broader clinical arena, Prog. Cardiovasc. Dis., 59, 135, 10.1016/j.pcad.2016.07.005 Guan, 2015, Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 35, 996, 10.1161/ATVBAHA.114.304785